文献速递膀胱癌与上尿路尿路上皮癌

液体摄入与非肌层浸润性膀胱癌患者复发和进展风险的关系

Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-01-25

基于多中心前瞻性队列 UroLife 数据,评估诊断前和诊断后液体摄入与非肌层浸润性膀胱癌(NMIBC)复发及进展风险的关联。中位随访 4.6 年,474 例患者出现一次或多次复发,142 例进展。诊断前液体摄入最高者首次复发风险升高,诊断前后液体摄入每增加 150 mL/天与进展风险升高相关。

要点

  • 诊断前液体摄入最高(≥2300 vs 1500-1900 mL/天)者首次复发风险升高(HR 1.38,95% CI 1.07-1.79)。
  • 诊断后液体摄入最高者未见首次复发风险升高。
  • 诊断前后液体摄入每增加 150 mL/天与进展风险升高相关(诊断后3个月FFQ:HR 1.05,95% CI 1.01-1.09)。

核心结论

  • 高液体摄入可能与更高的NMIBC复发风险、尤其是进展风险相关,但缺乏明确解释,可能与膀胱壁广泛扩张或泌尿系统症状有关,需进一步研究。

研究设计与样本

  • 多中心前瞻性队列研究UroLife,参与者于诊断后6周报告诊断前液体摄入(食物频率问卷,n=1322),于诊断后3和15个月报告诊断后液体摄入(食物频率问卷和4天24小时液体日记,n=1275)。

主要发现

  • 中位总随访4.6年期间,474例患者出现一次或多次复发,142例出现进展。
  • 诊断前液体摄入最高(≥2300 vs 1500-1900 mL/天)者首次复发风险升高(HR 1.38,95% CI 1.07-1.79),诊断后液体摄入最高者未见升高。
  • 多次复发风险的HR与首次复发相似。
  • 诊断前后液体摄入每增加150 mL/天均与进展风险升高相关(诊断后3个月FFQ:HR 1.05,95% CI 1.01-1.09;日记:HR 1.04,95% CI 0.99-1.09)。

临床怎么用

  • 作者认为这些发现不支持向NMIBC患者推荐增加液体摄入以降低复发或进展风险。

局限性

  • 这些发现缺乏明确解释,可能与膀胱壁广泛扩张或泌尿系统症状有关。
  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the association of pre- and post-diagnosis fluid intake with non-muscle-invasive bladder cancer (NMIBC) recurrence and progression risk. PATIENTS AND METHODS: Data were used from the multicentre prospective cohort study UroLife. Participants reported pre-diagnosis fluid intake at 6 weeks (food frequency questionnaire [FFQ]) (n = 1322) and post-diagnosis fluid intake at 3 and 15 months (FFQ and 4-day 24-h fluid diaries) (n = 1275) after diagnosis. Multivariable proportional hazard regression models were used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of fluid intake with risk of first and multiple recurrence(s) and progression. RESULTS: During a median overall follow-up of 4.6 years, 474 patients had one or more recurrence and 142 had progression. A higher first recurrence risk was observed for patients with the highest pre-diagnosis fluid intakes (≥2300 vs 1500-1900 mL/day: HR 1.38, 95% CI 1.07-1.79), but not for those with the highest post-diagnosis fluid intakes. HRs were similar for multiple recurrence risk. For progression, each 150 mL/day increase in both pre- and post-diagnosis fluid intake was consistently associated with an increased risk (post-diagnosis [3 months] FFQ-based: HR 1.05, 95% CI 1.01-1.09 and diary-based: HR 1.04, 95% CI 0.99-1.09). CONCLUSION: High fluid intakes may be associated with higher NMIBC recurrence and especially progression risk. These findings lack a clear explanation but may be related to extensive expansion of the bladder wall or urinary symptoms. Further research is warranted. Meanwhile, these findings do not support recommending high(er) fluid intakes to patients with NMIBC to decrease their recurrence or progression risk.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Beeren I, Meijer H, van der Heijden AG, et al. Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 39865397. doi:10.1111/bju.16665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。